{
    "ticker": "RDHL",
    "name": "Redhill Biopharma Ltd.",
    "description": "Redhill Biopharma Ltd. is a biopharmaceutical company focused on the development of innovative therapies for gastrointestinal diseases and other serious conditions. Founded in 2009 and headquartered in Tel Aviv, Israel, Redhill is committed to addressing unmet medical needs through its robust pipeline of drug candidates. The company's lead product, RHB-104, is being investigated for the treatment of Crohn's disease and is based on a unique combination of antibiotics targeting the underlying infections believed to contribute to this condition. In addition to RHB-104, Redhill is actively developing RHB-102, a proprietary formulation for the treatment of nausea and vomiting, and RHB-106, an oral capsule designed for bowel cleansing prior to colonoscopy. Redhill's approach combines rigorous scientific research with a focus on patient-centric solutions, aiming to provide effective therapies with favorable safety profiles. The company strategically collaborates with various research institutions and pharmaceutical partners to advance its clinical programs and expand its impact in the biopharmaceutical sector.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Tel Aviv, Israel",
    "founded": "2009",
    "website": "https://www.redhillbio.com",
    "ceo": "Micah A. Hill",
    "social_media": {
        "twitter": "https://twitter.com/RedhillBio",
        "linkedin": "https://www.linkedin.com/company/redhill-biopharma"
    },
    "investor_relations": "https://www.redhillbio.com/investors",
    "key_executives": [
        {
            "name": "Micah A. Hill",
            "position": "CEO"
        },
        {
            "name": "Mark L. Pomerantz",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gastrointestinal Therapies",
            "products": [
                "RHB-104",
                "RHB-102",
                "RHB-106"
            ]
        }
    ],
    "seo": {
        "meta_title": "Redhill Biopharma Ltd. | Innovative Gastrointestinal Therapies",
        "meta_description": "Explore Redhill Biopharma Ltd., a biopharmaceutical company dedicated to developing innovative therapies for gastrointestinal diseases and serious conditions. Learn more about our products and pipeline.",
        "keywords": [
            "Redhill Biopharma",
            "Gastrointestinal Therapies",
            "RHB-104",
            "Crohn's Disease",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Redhill Biopharma known for?",
            "answer": "Redhill Biopharma is known for developing innovative therapies for gastrointestinal diseases, including Crohn's disease."
        },
        {
            "question": "Who is the CEO of Redhill Biopharma?",
            "answer": "Micah A. Hill is the CEO of Redhill Biopharma Ltd."
        },
        {
            "question": "Where is Redhill Biopharma headquartered?",
            "answer": "Redhill Biopharma is headquartered in Tel Aviv, Israel."
        },
        {
            "question": "What are Redhill's main products?",
            "answer": "Redhill's main products include RHB-104, RHB-102, and RHB-106, targeting gastrointestinal conditions."
        },
        {
            "question": "When was Redhill Biopharma founded?",
            "answer": "Redhill Biopharma was founded in 2009."
        }
    ],
    "competitors": [
        "AMRN",
        "VYGR",
        "CRBP",
        "INFI"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRNA",
        "BMY"
    ]
}